Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, addressing a variety of unmet medical needs. Flagship was a co-founder of Quanterix, and co-led the Series A financing.

General Partner Doug Cole is on the Board.

www.quanterix.com